Educational information only. Not medical advice.

Research Memos

Dihexa vs Cerebrolysin

Dihexa is a defined synthetic peptidomimetic with rodent research and important publication warnings. Cerebrolysin is a porcine-brain-derived mixture with randomized human trials, including favorable rehabilitation findings and unsuccessful acute-stroke comparisons. There is no direct trial establishing which is more effective or safer, and neither a shared brain-research theme nor separate study results makes the preparations interchangeable.

Research reviewed October 15, 2026. Educational information only.

A defined molecule and a manufactured mixture

Dihexa and Cerebrolysin appear together in discussions of brain repair, but the names describe different materials. Dihexa, or PNB-0408, is a defined synthetic molecule retaining selected peptide features, called a peptidomimetic: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Its structure was developed from an angiotensin IV analogue. Cerebrolysin is a mixture of small peptides and free amino acids derived from porcine brain proteins. It has no one sequence, formula or molecular mass that represents all its constituents.

That chemistry changes the research problem. For Dihexa, an exposure assay can target the parent molecule. For Cerebrolysin, an assay must specify a constituent or validated marker before a concentration has a clear meaning. The product’s labeled concentrate mass is not the amount of a single active peptide. Clinical evidence also belongs to the manufactured preparation studied; a shared name on a different product does not establish the same composition or effects.

The main differences

What material was actually studied?

These are different kinds of preparation. Product identity matters before an outcome or exposure measurement is compared.

Dihexa

Dihexa / PNB-0408 is a defined synthetic angiotensin-IV-derived peptidomimetic. The parent chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide.

Sources

Cerebrolysin

Cerebrolysin is a porcine-brain-derived mixture of small peptides and free amino acids, supplied as a manufactured injectable solution. No single sequence or molecular mass describes it.

Sources

What did the neurological studies find?

No direct trial compares the two. These examples test different disease models and outcomes, so their results cannot rank clinical effectiveness.

Dihexa

Dihexa-treated APP/PS1 mice found a hidden swimming-maze platform faster than mice with the same genetic changes given preparation without Dihexa. In a separate experiment, head-injured rats given Dihexa directly into a brain ventricle made more correct delayed maze choices than injured rats given buffered salt solution (DPBS). The original pharmacology report has a Notice of Concern; the 2014 mechanism paper was retracted. No human benefit was established.

Sources

Cerebrolysin

In CARS, 208 people received standardized early stroke rehabilitation plus Cerebrolysin or saline. The Cerebrolysin group improved more from baseline to day 90 on arm-and-hand tasks. That result concerns rehabilitation after stroke, rather than general cognitive enhancement.

Sources

Where were results unfavorable or uncertain?

The Dihexa experiment tested toxin-induced problems in rats. The Cerebrolysin trials assessed recovery after human stroke, using planned clinical outcomes.

Dihexa

In a five-week study of 40 male rats, Dihexa did not protect measured movement, learning or weight-gain outcomes from the toxin 3-nitropropionic acid. The precision of any remaining treatment effect is unclear.

Sources

Cerebrolysin

CASTA did not establish its planned combined recovery benefit in 1,070 acute-stroke patients. A separate 119-person trial adding Cerebrolysin to alteplase did not establish better day-90 disability. Favorable secondary or post hoc results do not replace those main outcomes.

Sources

What is known about measured exposure and half-life?

Rat plasma measurements, direct brain administration and clinical follow-up times answer different questions. None supplies an interchangeable human half-life.

Dihexa

A 2013 rat report under a Notice of Concern calculated terminal plasma half-lives of 12.68 days intravenously and 8.83 ± 2.41 days intraperitoneally (mean ± standard error), with four rats in the latter analysis. These are not validated human estimates. FDA reports no identified human exposure data for Dihexa acetate.

Sources

Cerebrolysin

The reviewed intravenous clinical trials do not provide a validated human concentration curve or a single half-life for the mixture. Follow-up at day 90 or week 24 measures clinical outcomes, not persistence of all active constituents in blood or brain.

Sources

What limits a safety comparison?

The size and kind of safety evidence differ. No shared trial establishes which preparation causes fewer harms.

Dihexa

Human safety is unestablished in the reviewed sources. FDA’s acetate assessment describes missing human exposure and safety information; animal learning experiments cannot quantify long-term or uncommon human harms.

Sources

Cerebrolysin

In the 2023 Cochrane stroke review, serious events that did not cause death occurred in 20 of 667 Cerebrolysin participants (3.0%) and 8 of 668 placebo participants (1.2%): pooled risk ratio 2.39 (95% confidence interval 1.10–5.23). The manufacturer states that Cerebrolysin is not FDA-registered or approved for U.S. sale or distribution.

Sources

Dihexa’s early evidence has major publication warnings

The 2013 report introducing the Dihexa analogue and its rat learning and exposure measurements carries a 2021 Notice of Concern. A separate 2025 retraction withdrew the 2014 paper that argued its cognitive and synapse findings depended on HGF/c-Met signaling. The retraction states that an institutional investigation identified falsified or fabricated data in Figures 1B and 2A/C and a subsequent erratum submission. The withdrawn findings cannot establish the claimed mechanism.

Later experiments can still be assessed on their own design. Sun et al. (2021) reported better water-maze performance in APP/PS1 mice, a genetic model of selected Alzheimer-related changes. The paper describes administration inconsistently, limiting an oral-delivery claim. Martino and colleagues found better delayed maze choices after repeated mild head injury in rats given Dihexa directly into a fluid-filled cavity in the brain (ventricle). Conversely, the Wells et al. (2024) toxin experiment did not demonstrate protection of movement, learning or weight gain over five weeks. The results vary across these distinct animal models; none measured human cognitive outcomes.

Cerebrolysin has human results that depend on the clinical setting

The most consequential acute-stroke result comes from Heiss et al. (2012), CASTA. It assigned 1,070 people within 12 hours of ischemic stroke to Cerebrolysin or saline, alongside aspirin, and followed them for 90 days. The planned combined assessment of disability, daily activities and neurological deficits did not establish a treatment difference. More favorable findings in a more severe-stroke subgroup were post hoc and need confirmation.

The smaller CARS trial, reported by Muresanu and colleagues (2016), asked a more specific rehabilitation question. Its 208 participants received standardized rehabilitation plus Cerebrolysin or saline, starting 24–72 hours after stroke. The Cerebrolysin group improved more from baseline to day 90 on grasping, gripping and other arm tasks. The Mann–Whitney estimate was 0.71 (95% confidence interval 0.63–0.79). It compares the groups’ improvements: a randomly selected treated participant’s change tended to rank above a randomly selected control participant’s change, with tied changes shared equally. It does not describe the proportion who recovered. Different timing, rehabilitation and outcomes prevent treating CARS as a direct repeat of CASTA.

A separate Lang et al. (2013) trial added Cerebrolysin or placebo to alteplase, a clot-dissolving treatment. It stopped after the third interim analysis without establishing improved day-90 disability. In the Alvarez et al. (2006) Alzheimer trial, the lowest tested amount improved cognitive-test performance at 24 weeks; the higher two did not establish that cognitive improvement, although global clinical ratings favored all active groups. Human research exists, but it does not establish a benefit across every neurological setting.

Neither record supports a simple human half-life comparison

The long Dihexa half-lives often repeated online come from the 2013 rat report under a formal concern: 12.68 days after intravenous administration and 8.83 ± 2.41 days (mean ± standard error) after intraperitoneal administration, with four rats in the latter analysis. The intravenous concentrations rose again after an early decline. Those exploratory animal estimates do not establish human absorption, a human half-life or duration of a cognitive effect. The newer rat head-injury study delivered the compound directly into a fluid-filled cavity in the brain (ventricle) and therefore bypassed the usual blood-to-brain delivery question.

The reviewed Cerebrolysin clinical studies used intravenous administration but did not provide one validated human concentration curve or half-life for the mixture. A day-90 functional result does not show that an active constituent remained in the body for 90 days. Neither record supplies comparable human measurements of the parent compound or active constituents over time.

More clinical data does not mean every safety question is settled

FDA’s Dihexa acetate entry reports no identified human exposure data by any route and major gaps in safety information. The reviewed rodent studies cannot quantify uncommon human events, long-term cancer risk, pregnancy effects or interactions. The growth-factor hypothesis does not by itself establish either a human cancer hazard or safety.

For Cerebrolysin, the 2023 Cochrane review found an uncertain comparison for all serious adverse events and an increased rate of serious events that did not cause death: risk ratio 2.39, 95% confidence interval 1.10–5.23, in three trials with 1,335 participants. The manufacturer’s abbreviated Austrian information lists allergy to a component, epilepsy and severe renal impairment as contraindications. Its U.S. notice states that Cerebrolysin is not FDA-registered or approved for U.S. sale or distribution. These facts do not create a head-to-head safety comparison with Dihexa.

What can be compared responsibly

The compounds have reached different stages of investigation. Dihexa’s reviewed evidence is preclinical and partly constrained by publication warnings. Cerebrolysin has randomized clinical observations in neurological disease, with both favorable and unsuccessful findings. No identified direct trial assigned one shared population to these two preparations.

The next useful question is specific: improvement in which patient population, measured with which task or daily-life outcome, compared with what treatment and over how long? The existing studies cannot answer that question for Dihexa versus Cerebrolysin. They also do not justify replacing a clinical treatment, combining the compounds or treating one as an equivalent form of the other.

Frequently asked questions

Has one been shown to work better than the other?

No direct comparative trial was identified in the reviewed sources. Cerebrolysin’s human clinical studies and Dihexa’s rodent experiments differ in population, intervention, outcome and follow-up. Those separate studies cannot establish relative clinical effectiveness.

Does the retraction mean every later Dihexa result is false?

The retraction removes the 2014 paper as affirmative support for its claims. Later experiments require their own appraisal. A different laboratory, model or publication date does not automatically validate a result, and citing the withdrawn paper does not repair it.

Does Cerebrolysin have one active peptide sequence?

Cerebrolysin is a multicomponent animal-brain-derived preparation. A single peptide sequence, formula or molecular mass would misdescribe it. The product’s concentrate mass is not a measured amount of one active peptide.

Can CARS and CASTA be summarized as conflicting copies of the same study?

Their questions differ. CARS tested arm recovery alongside structured early rehabilitation; CASTA tested a planned combination of disability, daily activities and neurological deficits after acute stroke. Both results matter, with their own populations and outcomes.

Can the animal half-life determine how long a person would feel an effect?

The questioned Dihexa rat measurements cannot determine a human interval or clinical-effect duration. Cerebrolysin’s later clinical assessments likewise cannot substitute for concentration measurements of specified constituents. No personal administration schedule follows from this comparison.

Dihexa — full profile · Selected studies

Cerebrolysin — full profile · Selected studies

Compare other compounds · Explore the guide previews

References

  1. McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics. 2013;344(1):141–154. doi:10.1124/jpet.112.199497.

    Original PMC indexed full-text sections and PubMed figure legends accessed October 15, 2026. Direct PMC open returned a browser challenge. Read together with the 2021 Notice of Concern; full notice reasons were not acquired. Chemical design; Figure 2 tracer distribution; Figure 3 water maze; Figure 5 and Table 3 rat pharmacokinetics; Discussion.

  2. Journal of Pharmacology and Experimental Therapeutics. Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents, J Pharmacol Exp Ther, 344: 141-154; DOI: https://doi.org/10.1124/jpet.112.199497. 2021;378(3):313. doi:10.1124/jpet.112.199497concern.

    Original PubMed bibliographic notice opened October 15, 2026. No abstract or full notice text was available; no specific misconduct reason is assigned to this notice. PubMed title, notice linkage, date and DOI.

  3. Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. Retraction notice to “The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System” [J Pharmacol Exp Ther 351 (2014) 390-402]. Journal of Pharmacology and Experimental Therapeutics. 2025;392(4):103567. doi:10.1016/j.jpet.2025.103567.

    Complete original PMC and publisher retraction statement accessed October 15, 2026. Publisher URL: https://www.sciencedirect.com/science/article/abs/pii/S0022356525397806 . Full retraction statement: Figures 1B, 2A/C, subsequent erratum data; responsibility statement.

  4. Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 2021;11(11):1487. doi:10.3390/brainsci11111487.

    Original PubMed abstract and indexed original PMC Methods, Results and Discussion accessed October 15, 2026. Direct publisher retrieval failed; no separate correction/retraction was found in the checked original/indexed records and title/identifier searches. Methods 2.2; Results 3.1–3.2; Figure 2; PI3K inhibition experiments; Discussion route wording.

  5. Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Journal of Huntington’s Disease. 2024;13(1):55–66. doi:10.3233/JHD-231507.

    Original publisher page and original IOS Press indexed PDF abstract accessed October 15, 2026. Full methods, group denominators and outcome tables were not extracted. No correction/retraction was found in the checked publisher record or title search. Original abstract: 40 male Wistar rats, three randomized groups, five weeks and failure to protect.

  6. Martino KA, Nakhre A, Demarest RM, Devilbiss DM. Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury. Neurotrauma Reports. 2025;6(1):991–998. doi:10.1177/2689288X251392851.

    Original eight-page publisher PDF and indexed PubMed record accessed October 15, 2026. Supplementary methods were not acquired. No correction/retraction was found in the checked original records and title/identifier searches. PDF pages 2–5; Animals and surgery; Drug administration; Figure 1 delayed alternation and trial time; Figure 2 E-cadherin.

  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Dihexa acetate entry, substances nominated but withdrawn. Accessed October 15, 2026.

    Current official FDA page opened and Dihexa row read October 15, 2026. The entry concerns acetate; it does not establish tested equivalence with the parent research material. Dihexa acetate row under substances nominated but withdrawn.

  8. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630–636. doi:10.1161/STROKEAHA.111.628537.

    Original indexed PubMed abstract and original AHA PDF indexed passages accessed October 15, 2026. Direct PubMed open returned a shell; complete outcome and safety tables were not acquired. Abstract Methods/Results; original PDF introduction for porcine-brain origin; primary combined test and post hoc severity analysis.

  9. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151–159. doi:10.1161/STROKEAHA.115.009416.

    Original PubMed abstract and indexed original PMC full-text Methods and Results accessed October 15, 2026. Direct PMC open returned a browser challenge. Exact adverse-event tables were not extracted. Abstract; Methods Study Design and Treatment Regimen; Results Action Research Arm Test; trial sponsorship and safety.

  10. Lang W, Stadler CH, Poljakovic Z, Fleet D; Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke. 2013;8(2):95–104. doi:10.1111/j.1747-4949.2012.00901.x.

    Complete original Wiley publisher abstract accessed October 15, 2026 at https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1747-4949.2012.00901.x . Direct PubMed open returned a shell. Full journal article and outcome tables not acquired. Original abstract: 119 patients; sequential trial stopped at third interim analysis; day-90 modified Rankin Scale.

  11. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. European Journal of Neurology. 2006;13(1):43–54. doi:10.1111/j.1468-1331.2006.01222.x.

    Original PubMed abstract and original Wiley full-text indexed Methods and Results accessed October 15, 2026. The abstract prints P>0.001 for one global result; that inconsistent inequality is not reused. Abstract; Methods; Patient disposition: 279 randomized, 269 treated, 251 efficacy set, 237 completed; week-24 ADAS-cog/CIBIC results.

  12. Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases. 2011;20(4):310–318. doi:10.1016/j.jstrokecerebrovasdis.2010.01.012.

    Complete original PubMed abstract accessed October 15, 2026. Full methods, missing-data tables and adverse-event tables not acquired. Abstract Methods/Results: 242 participants, two treatment cycles, ADAS-cog+ changes and adjusted between-group difference; CIBIC+ assessment.

  13. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research. 2010;88(15):3275–3281. doi:10.1002/jnr.22495.

    Original PubMed abstract and original PMC full text freshly accessed October 15, 2026. Experimental protocols directly read and confirm intraperitoneal administration for 21 days and ten rats per dose-response/delayed-start group; full numerical tables were not extracted. Original record did not display a linked correction/retraction. The separate corrected 2013 Sonic hedgehog paper is not used. Abstract: embolic middle cerebral artery occlusion, 28-day cell measurements, 21-/28-day behavior, infarct-volume result and PI3K/Akt blockade.

  14. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2023;10:CD007026. doi:10.1002/14651858.CD007026.pub7.

    Original Cochrane review indexed PMC full-text abstract and trial descriptions accessed October 15, 2026. Exact 2023 author list, issue and pub7 DOI freshly confirmed in original PubMed record 37818733. Secondary synthesis, used for appraisal and safety rather than counted as a new treatment trial. Abstract Main results and conclusions; serious adverse events: RR 1.16 (0.81–1.66), nonfatal serious adverse events RR 2.39 (1.10–5.23), 3 trials/1,335 participants; trial descriptions.

  15. EVER Neuro Pharma GmbH. A comprehensive overview of Cerebrolysin®: prescribing information based on the Austrian Summary of Product Characteristics. Accessed October 15, 2026.

    Current official manufacturer page opened/indexed text accessed October 15, 2026. Abbreviated Austrian information, not a complete independently acquired national label and not U.S. approval. Prescribing information: 215.2 mg concentrate per mL; sodium hydroxide and water for injection; contraindications; country-specific scope; U.S. visitor notice.